Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept

Duret, Pierre-Marie; Sebbag, E.; Mallick, Auriane; Gravier, Simon; Spielmann, Lionel; Messer, Laurent

doi:10.1136/annrheumdis-2020-217362

Cited by 67 publications

(55 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients with prior autoimmune and autoinflammatory conditions infected with SARS-CoV-2 have shown better outcomes may be due to baseline immunomodulatory medications. Some reports have shown that patients with ADs with prior treatment with hydroxychloroquine, TNFα antagonists [134], Anakinra [135], or Tocilizumab [136], may develop a mildest SARS-CoV-2 infection. These phenomena could be associated with a better control to COVID-19, and it may suggest that these medications, used chronically, decrease the severity of this infection.…”

Section: Cytokine Storm Syndrome (Css)mentioning

confidence: 99%

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Rodríguez

Novelli

Rojas

et al. 2020

Journal of Autoimmunity

275

281

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Cytokine Storm Syndrome (Css)mentioning

confidence: 99%

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Rodríguez

Novelli

Rojas

et al. 2020

Journal of Autoimmunity

275

281

View full text Add to dashboard Cite

show abstract

“…18 . There are also a couple of case reports on anti-TNF- agents etanercept 19 and infliximab 20 therapy used successfully for COVID-19 patients with pre-existing auto-immune conditions. However, results of wider application of such therapy is still awaited.…”

Section: Introductionmentioning

confidence: 99%

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Dhar¹,

Vishnupriyan²,

Damodar³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: SARS-CoV-2, an infectious agent behind the ongoing COVID-19 pandemic, induces high levels of cytokines in patients contributing to the disease patho-physiology. Nonetheless, exact association and contribution of particular cytokines towards COVID-19 pathology remains poorly understood. This study performed a comprehensive meta-analysis to establish association between induced cytokines and COVID-19 disease severity to help in prognosis and clinical management. Methods: Scientific literature was searched to identify 18 clinical studies. Standardized mean difference (SMD) for cytokines IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ between severe and non-severe COVID-19 patient groups were summarized using random effects model. A classifier was built using logistic regression model with cytokines having significant SMD as covariates. Results: Out of the 6 cytokines, IL-6 and IL-10 showed statistically significant SMD across the studies synthesized. Classifier with mean values of both IL-6 and IL-10 as covariates performed well with accuracy of ~ 92% that was significantly higher than accuracy reported in literature with IL-6 and IL-10 as individual covariates. Conclusions: Simple panel proposed by us with only two cytokine markers can be used as predictors for fast diagnosis of patients with higher risk of COVID-19 disease deterioration and thus can be managed well for a favourable prognosis.

show abstract

“…4 In mice, TNFα blockade or the loss of TNFα receptor showed to reduce mortality or morbidity related to SARS-CoV2 infection. 5 Duret et al 6 reported a case of a patient treated with etanercept for spondyloarthropathy who rapidly recovered from COVID-19. Conti et al 7 described a case of a 67-year-old-psoriatic patient treated with adalimumab that did not develop any COVID-19 related symptom after several close contacts with COVID-19 confirmed cases.…”

mentioning

confidence: 99%

Non‐complicated evolution of COVID ‐19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab

Valenti

Facheris

Pavia

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The COVID-19 (coronavirus disease 2019) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), started in December 2019 in Wuhan, China, has been recently declared a pandemic 1 by the World Health Organization (WHO), becoming a major health concern worldwide. The pathogenesis of the disease is still under investigation, but it seems to be strictly related to an uncontrolled immune response that leads to a massive cytokine storm and subsequently to tissue damage. 2 Different immunomodulator treatments have been proposed to contrast this potentially fatal cytokine release syndrome, including (IL)-6 receptor inhibitors (tocilizumab; sarilumab), an IL-1 receptor antagonist (anakinra) and jak-inhibitors, such as baricitinib. Furthermore, another drug class, TNFα inhibitors, has been considered for SARS coronavirus infection. 3

show abstract

Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept

Cited by 67 publications

References 6 publications

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Non‐complicated evolution of COVID ‐19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab

Contact Info

Product

Resources

About